



GMP Compliance Menu

Search

[GMP Certificates](#)[Non-Compliance Report](#) Exclude Teleconference info

The Spanish Agency Of Medicines And Medical Devices

Report No: **NCF/NC2023/002/CAT****STATEMENT OF NON-COMPLIANCE WITH GMP****Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer⁽¹⁾****Part 1**

Issued following an inspection in accordance with :
 Art. 111(7) of Directive 2001/83/EC as amended
 Art. 94(2) of Regulation (EU) 2019/6 as amended

The competent authority of Spain confirms the following:

The manufacturer: **Serra Pamies S.A.**

Site address: **Avinguda Castellvell 24, Reus, 43206, Spain**

OMS Organisation Id. / OMS Location Id.: **ORG-100017839 / LOC-100026600**

Other

(Human) Royal Legislative Decree 1/2015, of July 24, and Royal Decree 824/2010 of 25 June.

(Veterinary) Royal Legislative Decree 1/2015, of July 24, and Royal Decree 824/2010 of 25 June.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2023-05-23**, it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

- The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and Commission Delegated Regulation (EU) 2017/1569 and Directive 91/412/EEC
- The principles and guidelines of Good Manufacturing Practice laid down in Directive 91/412/EC Article 93(2) of Regulation (EU) 2019/6

(1) The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.

Part 2

Human Medicinal Products

Veterinary Medicinal Products

1 NON-COMPLIANT MANUFACTURING OPERATIONS**1.1 Sterile products**

1.1.2 *terminally Sterilised (processing operations for the following dosage forms)*

1.1.2.3 Small volume liquids

1.1.3 *Batch certification*

1.2 Non-sterile products

1.2.1 *Non-sterile products (processing operations for the following dosage forms)*

1.2.1.1 Capsules, hard shell

1.2.1.6 Liquids for internal use

1.2.1.8 Other solid dosage forms

1.2.1.13 Tablets

1.2.2 *Batch certification*

1.5 Packaging

1.5.1 *Primary Packaging*

1.5.1.1 Capsules, hard shell

1.5.1.6 Liquids for internal use

1.5.1.8 Other solid dosage forms

1.5.1.13 Tablets

1.6 Quality control testing

1.6.1 *Microbiological: sterility*

Clarifying remarks (for public users):

1.2.1.5 Oral liquids for external use are also included in this Statement of Non GMP compliance

Part 3

Nature of non-compliance: During the inspection carried out in May and June 2023, a lack of compliance with Part I of the EU-NCF was detected. Sixty-three (63) deficiencies were identified in total, nineteen (19) of them were classified as major. Important deficiencies were identified in the quality management system and the management's assurance of the provision of this system, in process validations, in software validations, in data integrity, in cleaning validations, in the management of personnel and their training, in the calibration of measuring and control instruments, in the management of expired raw materials, in the management of the autoclave, in the management of reprocesses, in the qualification of manufacturing and control clean areas, in the management of OOS, in the validation of analytical methods, in the analysis and release of Morphine, in the analysis of endotoxins, in the analysis of Muciplazma, in the management of donations and in self-inspections.

<p>Action taken/proposed by the NCA:</p> <p>Suspension of the manufacturing authorisation No. 0417 in Part The activity of manufacturing of sterile and oral (hard capsules, liquids, other solid pharmaceutical forms and tablets) human and veterinary medicinal products, including primary packaging and certification of these dosage forms and microbiological quality control: sterile, has already been suspended as a precautionary measure. This measure has adopted due to the possible risk to animal/public health that may occur as a result of the criticality of the deficiencies identified during the inspection. This measure will be maintained until all the deficiencies observed in the inspection have been corrected and it has been verified, through a new inspection. This measure includes, in addition, the prohibition of placing on the market of any injectable, oral solid and liquid for internal use medicine that has been manufactured in the facilities of this pharmaceutical laboratory.</p> <p>Recall of batches already released No specific quality defects on concrete batches present in the market were detected, and thus no action/recall is deemed necessary against concrete batches released and placed on the market.</p> <p>Additional comments: This statement of non-compliance is signed by Clara Pareja Rossell, Departament de Salut Direcció General d'Ordenació i Regulació Sanitària, Generalitat de Catalunya, and sent to Eudra GMDP by AEMPS.</p>

Teleconference Date:	Teleconference Time (CET):	Dial in no.:
-----------------------------	-----------------------------------	---------------------

2023-08-21

Name and signature of the authorised person of the Competent Authority of Spain

Confidential**The Spanish Agency Of Medicines And Medical Devices**Tel: **Confidential**Fax: **Confidential**

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please [click here](#) to get list of NCA's.

Due to the restrictions caused by COVID-19, the period of validity GMP and GDP certificates issued by EEA authorities is automatically extended until the end of 2023, except where clarifying remarks in the document state otherwise. Manufacturers, and importers and distributors must continue to comply with GMP/GDP and all other legal obligations. On-site inspections are conducted where and when possible. Competent authorities reserve the right to perform risk based supervision of sites by either on-site inspections or distant assessments and, based on the outcome, may continue to issue, withdraw or restrict GMP certificates, as appropriate.

For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMDP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.

As of 28 January 2022, the source of organisational data will change. Additional information and instructions are available on [EMA's website](#)

[EMA © 2014. EudraGMDP 6.5.0.9-bugfix2 build 2023/07/20 06:36]